Thromboembolic Risk of Thrombopoietin Receptor Agonists for Adult Primary Immune Thrombocytopenia: A Systematic Review and Meta‐Analysis Integrating Randomized Controlled Trials and Prospective Evidence
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy2025Vol. 45(11), pp. 764–773
Meng‐Fei Dai, Gina Chong, Wenxiu Xin, Sisi Kong, Junfeng Zhu, Like Zhong, Gaoqi Xu, Xiangyu Jin, Chaoneng He, Tingting Wang, Xiufang Mi, Liping Luo, Z.H. Song, Haiying Ding, Luo Fang
Abstract
This analysis demonstrates that TPO-RAs therapy increases the risk of thromboembolism, with the risk of arterial events becoming particularly pronounced during long-term use. These findings highlight the need for individualized risk assessment and vigilant monitoring in patients receiving TPO-RAs.